SEB Asset Management AB Takes $10.52 Million Position in Zoetis Inc. $ZTS

SEB Asset Management AB acquired a new position in shares of Zoetis Inc. (NYSE:ZTS) during the first quarter, Holdings Channel.com reports. The institutional investor acquired 88,974 shares of the company’s stock, valued at approximately $10,518,000.

Other hedge funds have also recently bought and sold shares of the company. Prosperity Bancshares Inc acquired a new stake in shares of Zoetis during the 4th quarter worth approximately $25,000. Lodestone Wealth Management LLC acquired a new position in Zoetis during the fourth quarter valued at approximately $30,000. Root Financial Partners LLC raised its position in Zoetis by 66.5% during the first quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after purchasing an additional 103 shares in the last quarter. Elyxium Wealth LLC bought a new stake in Zoetis during the fourth quarter worth $32,000. Finally, Global Assets Advisory LLC bought a new stake in Zoetis during the first quarter worth $38,000. 92.80% of the stock is owned by institutional investors.

Zoetis News Summary

Here are the key news stories impacting Zoetis this week:

• Positive Sentiment: Zoetis saw unusual options activity, with traders buying 8,095 call options, about 59% above the average daily volume, suggesting some speculative bullish interest.
• Neutral Sentiment: Several law firms, including Rosen Law Firm, Glancy Prongay Wolke & Rotter LLP, the Schall Law Firm, Bronstein Gewirtz & Grossman LLC, DJS Law Group, and Bragar Eagel & Squire, reminded investors about a July 27 lead-plaintiff deadline in an existing class action related to Zoetis securities purchased between January 14, 2025 and May 6, 2026. Article Title
• Negative Sentiment: The class-action campaign keeps attention on alleged securities-law violations, which can create legal uncertainty and pressure the stock until the case is resolved. Article Title

Zoetis Stock Down 0.5%

Zoetis stock opened at $76.17 on Tuesday. The company has a debt-to-equity ratio of 2.80, a quick ratio of 1.91 and a current ratio of 3.15. Zoetis Inc. has a 52-week low of $71.47 and a 52-week high of $160.48. The firm has a 50 day moving average price of $77.32 and a two-hundred day moving average price of $105.54. The firm has a market cap of $31.93 billion, a price-to-earnings ratio of 12.63, a PEG ratio of 1.19 and a beta of 0.75.

Zoetis (NYSE:ZTS) last issued its quarterly earnings results on Thursday, May 7th. The company reported $1.53 earnings per share for the quarter, missing analysts’ consensus estimates of $1.60 by ($0.07). The business had revenue of $2.26 billion for the quarter, compared to analyst estimates of $2.30 billion. Zoetis had a return on equity of 66.85% and a net margin of 27.80%.The business’s revenue was up 2.9% on a year-over-year basis. During the same quarter in the previous year, the business posted $1.48 earnings per share. Zoetis has set its FY 2026 guidance at 6.850-7.000 EPS. Equities analysts predict that Zoetis Inc. will post 6.87 EPS for the current year.

Zoetis Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Monday, July 20th will be issued a $0.53 dividend. This represents a $2.12 dividend on an annualized basis and a dividend yield of 2.8%. The ex-dividend date is Monday, July 20th. Zoetis’s dividend payout ratio (DPR) is currently 35.16%.

Analyst Ratings Changes

ZTS has been the topic of a number of recent analyst reports. Morgan Stanley reiterated an “overweight” rating and issued a $115.00 target price on shares of Zoetis in a research report on Friday, May 15th. Barclays dropped their target price on shares of Zoetis from $136.00 to $85.00 and set an “equal weight” rating for the company in a report on Wednesday, July 1st. Citigroup reduced their price target on shares of Zoetis from $145.00 to $112.00 and set a “buy” rating on the stock in a research note on Monday, May 18th. HSBC decreased their price target on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a report on Monday, July 6th. Finally, TD Cowen lowered their price objective on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating for the company in a research report on Tuesday, June 30th. Eight analysts have rated the stock with a Buy rating, eight have issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, Zoetis has an average rating of “Hold” and an average price target of $120.83.

Insider Buying and Selling

In related news, Director Paul Bisaro bought 2,000 shares of the company’s stock in a transaction dated Wednesday, May 13th. The shares were bought at an average price of $75.88 per share, for a total transaction of $151,760.00. Following the completion of the acquisition, the director directly owned 27,862 shares of the company’s stock, valued at $2,114,168.56. This trade represents a 7.73% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Frank A. Damelio acquired 6,650 shares of the company’s stock in a transaction on Wednesday, May 13th. The shares were bought at an average price of $75.39 per share, for a total transaction of $501,343.50. Following the completion of the purchase, the director owned 21,458 shares in the company, valued at approximately $1,617,718.62. This represents a 44.91% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have bought a total of 11,650 shares of company stock worth $886,384 in the last ninety days. Corporate insiders own 0.22% of the company’s stock.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.